Skip to main content
. 2022 Jan 26;14(3):625. doi: 10.3390/cancers14030625

Table 12.

Retrospective clinical studies using RT and CT in combination with HT.

Author(s) Cancer Site, n CT Drug (s)(mg/m2) ×
Cycles		 RT Dose (Gy)
/Fractions		 Temperature
Metrics (°C)		 Session ttreat
(min)		 Thermal
Dose (min)		 tint (min) Sequence Clinical Outcome
(Comment)
Zhu et al. [163] Locally
advanced esophageal
cancer,
n = 78		 450
5-fluorouracil
five times weekly
× 4–6
25 cisplatin
five times weekly
× 4–6
6		 60.0–66.0
/30–33		 n.r. Ntotal:
6–12
Nweek:
2		 60 n.r. 120 n.r.

  • CR 1: 39.7% (31/78), PR 2: 56.4% (43/78), SD 3: 3.9% (3/78).

  • 1-, 2- and 3-year LRC 4: 76.9%, 55.1% and 47.4%, respectively;

  • 1-, 2- and 3-year DMFS 5: 67.9%, 38.5% and 30.8% respectively;

  • 1-, 2- and 3-year OS 6: 67.9%, 41.0% and 33.3%, respectively

(correlation of thermometric parameters with clinical outcome not presented)
Ohguri et al. [148] Locally
advanced pancreatic cancer,
n = 20		 Group A:
40–50
gemcitabine
twice weekly
× 4
Group B:
200–500
gemcitabine
once weekly
× 3		 50.4–64.8
/28–36		 n.r. Ntotal:
6
Nweek:
1		 n.r. n.r. Group A:Instant
Group B:
60–180		 HT after CT&RT

  • Grade II-IV hematological toxicities: 8 patients.

  • The objective tumor response, CR for 1 patient, PR for 4, and NC 7 for 15.

  • DM 8: 13 and LF 9: 5 patients.

  • DPFS 10: 8.8 months, OS ‡: 18.6 months.

  • The treatment regimen did not correlate with the survival rates.

(correlation of thermometric parameters with clinical outcome not presented)
Gani et al. [164] Locally
advanced
rectal
cancer,
n = 60		 1000
5-fluorouracil
× 4		 50.4/28 T90 ‡: 39.3 (37.1–40.6) Ntotal ‡:
4
Nweek:
1–2		 60 CEM43°C ‡:
1.1 (0.0–9.2)		 n.r. n.r.

  • 5-year OS, DFS 11, local control and DMFS were 83%, 75%, 93% and 76%, respectively.

  • No impact of HT on DFS and DMFS.

  • Ntotal not predictive for OS, DFS, LC, or DMFS.

Postoperative nodal stage remained a significant prognosticator for OS, DFS and DMFS (multivariate analysis).
Merten et al. [165] Bladder
cancer,
n = 79		 20 cisplatin
5 times weekly
× 2
600
5-fluorouracil
5 times weekly
× 2		 50.4–55.8/
28–31		 n.r. Ntotal:
5–7
Nweek:
1		 60 n.r. 0–60 RT after
concurrent
CT&HT

  • CR: 87% (67/77).

  • 5- and 10-year OS: 87% and 60%, respectively.

  • 5- and 10-year DFS to 66% and 46% respectively.

  • Acute toxicity, grade III: 11% and grade IV: 3%.

  • Late toxicity, grade III: 1.3%.

(correlation of thermometric parameters with clinical outcome not presented)
van Haaren et al. [166] Esophageal
cancer,
n = 29		 50 paclitaxelonce weekly
× 5
and
carboplatin (AUC=2)
once weekly
× 5		 41.4/23 T90 †: 38.6 ± 0.5
T50 †: 39.2 ± 0.6
T10 †: 40.1 ± 0.8		 Ntotal:
5
Nweek:
1		 60 n.r. 0–60 HT after
CT & RT

  • CR: 19% (5/29), mPR 12: 26% (7/29), PR: 33% (9/29) and SD: 22% (6/29).

  • The dependence of T50 on the body size parameters was substantial.

(correlation of thermometric parameters with clinical outcome not presented)

n: number of patients assigned to be treated with HT in combination with RT; †: mean value (±standard deviation) or mean value (range); ‡: median (range); 1 CR: complete response; 2 PR: partial response; 3 SD: stable disease; 4 LRC:locoregional control, 5 DMFS: distant metastasis-free survival; 6 OS: overall survival; 7 NC: no change; 8 DM: distant metastases; 9 LF: local failure; 10 DPFS: disease progression-free survival; 11 DFS:disease free survival; 12 mPR: partial remission with only residual microscopic tumor foci.